A 6.4-kb DNA fragment containing the DNA gyrase gyrA and gyrB genes was cloned and sequenced from the quinolone-susceptible Staphylococcus aureus type strain ATCC 12600. An expression plasmid was constructed by inserting the cloned genes into the Escherichia coli-S. aureus shuttle vector pAT19, and deletion plasmids carrying only functional gyrA and gyrB genes were derived from this plasmid. An efficient transformation system for S. aureus RN4220 was established by using these plasmids. Quinolone-resistant mutants ofS. aureus RN4220 were isolated by three-step selection with quinolones. The first-and second-step mutants were considered to be transport mutants, and the third-step mutants were divided into five groups with respect to
Fluoroquinolones are synthetic chemotherapeutic agents with broad and potent antibacterial activity against gramnegative and -positive organisms and have been used against various bacterial infections. Staphylococcus aureus is an important pathogenic organism causing a variety of local and systemic infections and was originally susceptible to quinolones (5) . Therefore, it was considered that quinolones might be useful for treating S. aureus infections, including those with methicillin-resistant S. aureus (MRSA), which are resistant to most available antibacterial agents. However, the usefulness of quinolones for MRSA infections has been limited, since the emergence of quinolone resistance has been found to be relatively rapid (27, 28) .
Unusual findings as to quinolone resistance in S. aureus are that some MRSA resistant to fluoroquinolones remain susceptible to sparfloxacin (17) and other newer quinolones (26) and that quinolone-resistant mutants can easily be obtained by single-step selection with ciprofloxacin and norfloxacin, but not with sparfloxacin (17) .
Three genes related to quinolone resistance in S. aureus have been reported so far: gyrA (6, 7, 30, 31) , norA (40) , andflq (33) . The gyrase genes of S. aureus have been cloned and sequenced (2, 21) , and analysis of PCR-generated fragments from quinolone-resistant S. aureus revealed that the gyrA mutations were similar to those responsible for quinolone resistance in Escherichia coli (7, 30, 31) . Since DNA gyrase reconstituted from the A subunit from quinolone-resistant S. aureus and the wild-type B subunit is quinolone resistant (24, 25) , it is suggested that gyrA mutations might cause quinolone resistance in S. aureus. However, transformation with the * Corresponding author. Mailing address: Bioscience Research Lab- oratories, Dainippon Pharmaceutical Co., Ltd., Enoki , Suita, Osaka 564, Japan. Phone: 81.6.3375909. Fax: 81.6.3387656. gyrase gene has not been successfully performed for S. aureus, and it is still unclear whether the gyrA mutations reported are really responsible for quinolone resistance in S. aureus. The norA gene has been cloned and sequenced, and it is considered to encode a quinolone efflux pump (40) . Interestingly, organisms transformed with a plasmid carrying the norA gene are resistant to relatively hydrophilic quinolones, such as norfloxacin, enoxacin, and ciprofloxacin, but are susceptible or less resistant to relatively hydrophobic ones, such as nalidixic acid, oxolinic acid, and sparfloxacin (40) . These results are accounted for by efficient excretion of hydrophilic quinolones and by inefficient excretion of hydrophobic quinolones through the pump (40) . The flq gene (33) located near the thr and trp genes on the S. aureus chromosome has not been cloned yet and its function is not known.
In order to clarify the relationship between gyrase mutations and quinolone resistance, we cloned the wild-type gyrA and gyrB genes of S. aureus type strain ATCC 12600, developed an efficient transformation system for quinolone-resistant spontaneous mutants of S. aureus RN4220, and analyzed the mutations in their gyrA and gyrB genes by both transformation and DNA sequencing.
MATERUILS AND METHODS
Bacterial strains and vectors. S. aureus type strain ATCC 12600 was purchased from Japanese Society for Bacteriology. S. aureus RN4220 (18) was kindly provided by R. P. Novick. E. coli HB101 and JM109, plasmids pBR322, pUC18, and pUC119, and phages M13mpl8 and M13mpl9 were purchased from Takara Shuzo Co., Ltd. (Kyoto, Japan). The VCS-M13 interference-resistant helper phage and a pT7Blue(R) Tvector kit were purchased from Stratagene cloning system (La Jolla, Calif.) and Novagen (Madison, Wis.), respectively. Plasmid pAT19 (32) (4) . Small-scale plasmid DNA isolation was carried out by the rapid boiling method described by Holmes and Quigley (11) or by the method of Birnboim and Doly (1), except that lysozyme was replaced by achromopeptidase (500 U/ml) for S. aureus. Large-scale plasmid DNA isolation was done by the method of Wilkie et al. (36) .
Transformation of E. coli and S. aureus. Transformation of E. coli was performed by the CaCl2 method (20) 400 ,ug/ml for pAT19 and its derivatives and ampicillin at 25 ,ug/ml for the other plasmids. Transformation of S. aureus was carried out as follows. Staphylococcal cells were prepared by the method of K. Hiramatsu (Juntendo University, Tokyo) (10) . One hundred microliters of the culture of S. aureus RN4220 and its quinolone-resistant mutants that had been grown overnight were inoculated into 10 ml of brain heart infusion broth and incubated at 37°C until an optical density at 600 nm of 0.3 to 0.5 was attained. The cells were harvested by centrifugation, suspended in 1 ml of 1.1 M sucrose, and transferred into an Eppendorf centrifuge tube. The cells were collected by centrifugation, washed twice in 0.5 ml of 1.1 M sucrose, and then resuspended in 80 RI of 1.1 M sucrose. Plasmid DNA (ca. 1 ,ug in a volume of 1 RI) was added to 20-pl aliquots of the cell suspension, which were then subjected to a high-voltage electric pulse with the Cell-Porator apparatus (Bethesda Research Laboratories, Gaithersburg, Md.); the conditions used were as follows: capacitance, 330 ,uF; voltage, 300 V; resistance, low fl, and booster, 2 kQi. The cells were mixed with 0.5 ml of brain heart infusion broth containing 1.1 M sucrose, incubated at 37°C for 2 h, spread onto brain heart infusion agar plates containing erythromycin at a concentration of 8 ,ug/ml, and then cultured at 37°C for 24 h.
DNA-DNA hybridization. Southern hybridization and colony hybridization for cloning of S. aureus gyrase genes from strain ATCC 12600 were carried out as described by Maniatis et al. (20) . Oligonucleotide probes complementary to the sequences of nucleotides 2155 to 2175 and 2314 to 2334 (see Fig. 3 ) were designed on the basis of information on the nucleotide sequence of the portion of the gyrB-gyrA genes of a clinical isolate of S. aureus (12) and were 2P labeled by using T4 polynucleotide kinase.
Construction of the plasmids for transformation. Plasmid pESSGO17 used in transformation with gyrase genes was constructed by inserting the 6.4-kb KpnI-PstI fragment containing the wild-type gyrB and gyrA genes of pSAGBA64HPM ( Fig.   1 ) between the KpnI and PstI sites of an E. coli-S. aureus shuttle vector, pAT19 (Fig. 2) . Plasmid pESSGO17AP carrying only the functional gyrA gene was constructed by deleting the 198-bp PmaCI-PmaCI segment (nucleotides 1160 to 1357) of the gyrB gene of pESSGO17 (Fig. 2) . Plasmid pESSGO17ABP having only the functional gyrB gene was obtained by deleting the 345-bp BalI and PflMI segment (nucleotides 2469 to 2814) of the gyrA gene of pESSGO17. gyrA and/or gyrB plasmids with the mutations were obtained through replacement of a small portion of the wild-type gyrA and/or gyrB genes by the corresponding fragments of the mutants. To replace the fragment in the gyrA gene, the 351-bp Aor5lHI-BalI fragments (nucleotides 2118 to 2468) from the pT7Blue(R) derivatives containing the PCR products of the gyrA mutants were ligated with the 12.6-kb Aor5lHI-BalI fragments of pESSGO17 and pESS G017AP. Fragment replacement in the gyrB gene was carried VOL. 38, 1994 on October 28, 2017 by guest http://aac.asm.org/ Downloaded from
Nucleotide sequences of the gyrB and gyrA genes of S. aureus ATCC 12600 (from 180 bp upstream of the initiation codon of the gyrB gene to 135 bp downstream of the termination codon of the gyrA gene). The nucleotide sequences of the sense strands of the genes are shown from the 5' end (left) to the 3' (right) end. The deduced amino acid sequences are given below the DNA sequences (GyrB, nucleotides 181 to 2112; GyrA, nucleotides 2152 to 4812). The -35 and -10 sequences of the putative promoter, and the presumptive Shine-Dalgamo (SD)-like sequences are underlined, and an inverted repeat which can act as a transcription terminator is underlined with arrows. out in the same manner with pESSGO17 and pESSGO17A&BP, Amplification of the segments of the S. aureus gyrA and gyrB the 12.1-kb NspV-Aor5lHI fragments of which were ligated genes corresponding to the quinolone resistance-determining with the 909-bp NspV-Aor5lHI fragments (nucleotides 1209 to regions of E. coli genes by PCR. One-hundred-microliter 2117) of the PCR products.
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FIG. 4.
Comparison of the amino acid sequences of the S. aureus and E. coli GyrA polypeptides. The sequences of S. aureus 81231, S. aureus 601055, and E. coli KL16 are from references 21, 2, and 41, respectively. The dashes indicate that the amino acid residues are identical to those of S. aureus ATCC 12600. The dots indicate that the amino acid residues are absent. The sites of S. aureus corresponding to quinolone resistance-determining sites (38) and the DNA-binding site (14) of E. coli are indicated by * and V above the amino acid residues, respectively. The putative leucine zipper structure (19) is overlined with arrows. 30 s at 74°C; 2 cycles of 15 s at 94°C; 30 s at 63°C; 3 min at 74°C. The PCR products were directly cloned into pT7Blue(R) T-vector.
DNA sequencing. The DNA sequences of the gyrase genes were determined by the dideoxy chain termination method with the phage M13mpl8 and M13mpl9 vectors and E. coli JM109. DNA sequencing of the PCR products was carried out as follows. The PCR products were cloned into plasmid pT7Blue(R) T-vector and transformed into E. coli JM109, and then single-stranded DNA was prepared by the method of Vieira and Messing (34) using the VCS-M13 interferenceresistant helper phage. The DNA sequences were determined by the dideoxy chain termination method with a BcaBEST dideoxy sequencing kit and synthetic oligonucleotide primers. Other DNA techniques were done essentially as described by Maniatis et al. (20) .
Nucleotide sequence accession number. Nucleotide sequence accession number D10489 has been assigned to the sequence of strain ATCC 12600 containing the gyrB and gyrA genes in the DDBJ, EMBL, and GenBank data bases.
RESULTS
Cloning of the DNA gyrase genes from quinolone-susceptible S. aureus ATCC 12600. Southern hybridization analysis using the oligonucleotide probes described in Materials and Methods showed that the 6.5-kb HindIII and 5-kb EcoRI DNA fragments derived from S. aureus ATCC 12600 might contain the gyrase genes, and these two fragments were inserted into the HindIII and EcoRI sites, respectively, of pBR322. E. coli HB101 was transformed with the resultant plasmids, and about 20 hybridization-positive clones were selected in each case. Restriction analysis and nucleotide sequencing suggested that pSAGB301 and pSAGA501 had the gyrase genes (Fig. 1) (39) , the sites for ATP binding (35) , and the sites causing coumarin antibiotic resistance (3) of E. coli are indicated by *, *, and * above the amino acid residues, respectively. 4.2-kb XbaI-EcoRI fragment from pSAGA501 was subcloned between the XbaI and EcoRI sites of pUC18, and then a 4-kb XbaI fragment from pSAGB301 was inserted into the XbaI site of the resultant plasmid in the right direction to obtain pSAGBA085 containing the entire gyrB and gyrA genes. A truncated plasmid, pSAGBA64HPM, was constructed by inserting a 6.4-kb filled-in PacI-MamI fragment from pSAG BA085 into the HincIl site of pUC119 (Fig. 1) .
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Nucleotide sequences of the gyrase genes of S. aureus ATCC 12600. The nucleotide sequence of the cloned fragment containing the gyrase genes in pSAGBA085 is shown with the deduced amino acid sequence in Fig. 3 (2, 21) and E. coli reported previously (37, 41) in Fig. 4 and 5. For the GyrA polypeptide (Fig. 4) Selection of quinolone-resistant mutants of S. aureus RN4220. Spontaneous quinolone-resistant mutants were isolated from S. aureus RN4220, since an efficient transformation system was found with the combination of S. aureus RN4220 and plasmid pAT19. The transformation frequency of S. aureus ATCC 12600 from which the gyrA and gyrB genes were cloned was too low.
An attempt was first made to select spontaneous quinoloneresistant mutants of S. aureus RN4220 with sparfloxacin, ciprofloxacin, norfloxacin, and oxolinic acid at four times their MICs (Table 1) . Mutants were detected at frequencies of 3 x 10-8 and 1.3 x 10-7, respectively, when ciprofloxacin and norfloxacin were used as the selective agent, but no mutants were detected when sparfloxacin or oxolinic acid was used as the selective agent. The mutants selected by ciprofloxacin and norfloxacin were 8 to 16 times more resistant to the quinolones used for selection than the parental strain was (Table 1) but only 2 times more resistant to sparfloxacin and oxolinic acid than RN4220 was (Table 2 and data not shown). Second-step mutants were obtained from representative mutants, RCM101 and RNM101, by ciprofloxacin and norfloxacin selection (four times the MICs for the first-step mutants) at frequencies of 2.5 x 10-8 and 1.1 x 10-6, respectively. Ciprofloxacin-selected second-step mutants were 32 times more resistant to ciprofloxacin than RN4220 was, and norfloxacin-selected secondstep mutants were 64 to 128 times more resistant to norfloxacin than RN4220 was (Table 1 ). These second-step mutants were only two to four times more resistant to oxolinic acid and sparfloxacin than RN4220 was (Table 2 and data not shown). Third-step mutants were selected from a ciprofloxacin-selected second-step mutant, RCM1O1D, by using sparfloxacin, ciprofloxacin, and oxolinic acid at four times their MICs. Mutants were isolated by selection with ciprofloxacin and oxolinic acid at frequencies of >1.0 x 10-4 and 2.8 x 10-8, respectively.
Oxolinic acid-selected mutants were 16 to 64 times more resistant to oxolinic acid than RN4220 was and showed various patterns of resistance to sparfloxacin, ciprofloxacin, and norfloxacin (Table 2) . No mutants were detected on selection with sparfloxacin.
Quinolone resistance of oxolinic acid-selected third-step mutants of S. aureus RN4220. The 35 third-step mutants studied were classified into five groups according to their resistance patterns and the results of transformation with the gyrase genes described in the next paragraph. As shown in Table 2 Complementation test of the oxolinic acid-selected thirdstep mutants of S. aureus RN4220 with the wild-type gyrase genes. Table 3 shows the sparfloxacin susceptibilities of the oxolinic acid-selected third-step mutants of S. aureus RN4220 before and after transformation with the plasmids having the wild-type gyrase genes of ATCC 12600. Transformation of the group 1 and 2 mutants with plasmid pESSGO17 carrying both the gyrA and gyrB genes and plasmid pESSGO17AP carrying only the functional gyrA gene made them as sparfloxacin susceptible as the parent second-step mutant, RCM1O1D, but the transformants with pESSGO17ABP carrying only the functional gyrB gene were still quinolone resistant, suggesting that the group 1 and 2 mutants might have a gyrA mutation. Transformation of the group 3 and 4 mutants with pESSGO17 (gyrBA) and pESSGO17ABP (gyrB) made them sparfloxacin susceptible or resistant, but transformation with pESSGO17AP (gyrA) did not, suggesting that they might have agyrB mutation.
Transformation of the group 5 mutant with pESSGO17 (gyrBA) made it completely sparfloxacin susceptible, but transformation with pESSGO17AP(gyrA) and pESSGO17ABP(yrB) made it incompletely sparfloxacin susceptible, suggesting that it might have mutations on both the gyrA and gyrB genes.
Identification of mutations in the gyrase genes. The DNA sequences of S. aureus containing those corresponding to the quinolone resistance-determining regions of the E. coli gyrase genes were amplified by PCR and sequenced ( (17) reported that quinolone- VOL. 38, 1994 on October 28, 2017 by guest http://aac.asm.org/ Downloaded from resistant mutants of S. aureus can be isolated by ciprofloxacin and norfloxacin selection, but not by sparfloxacin selection, and Hori et al. (13) reported that quinolone-resistant mutants of S. aureus can be selected by norfloxacin and at low frequency by ofloxacin. Thus, in S. aureus, the frequency of isolation of mutants differs significantly, depending on the quinolone used for selection. One of the second-step mutants, RCM1O1D, accumulated ciprofloxacin to a lesser degree than RN4220 did (data not shown), and its level of quinolone resistance did not change on transformation with pESSGO17 having the wild-type gyrB and gyrA genes, suggesting that the strain is a transport mutant.
Because the oxolinic acid-selected mutants (third-step mutants) showed a variety of resistance patterns compared with those of the ciprofloxacin-selected mutants, they were used for further studies. They were considered to be gyrase mutants because their transformants with plasmids carrying the wildtype gyrase gene were quinolone susceptible. It is not clear why gyrase mutants could be obtained on third-step selection but not on first-and second-step selection. Hori et al. (13) suggested that gyrase mutations alone may be lethal and cannot exist without a suppressor mutation. However, this is unlikely because gyrase mutations alone are not lethal in E. coli (29, 41) . Further studies are required to clarify this point.
DNA sequence analyses of the 35 third-step mutants revealed that these mutants had the mutations on the gyrA and/or gyrB genes (Table 4) . These mutants transformed with the plasmids having the same mutations in the gyrA and/or gyrB genes remained quinolone resistant, indicating that these mutations were actually responsible for quinolone resistance. These complementation test results also indicate that the wild-type gyrA and gyrB genes are dominant over the corresponding mutant genes in S. aureus and thus can be used to determine whether a mutant has a mutation(s) in the gyrA and/or gyrB genes.
All the mutations in the gyrA gene detected in this study were reported previously for clinical isolates of S. aureus (7, 30, 31) , suggesting that the mechanism of quinolone resistance mutation in the gyrA gene of S. aureus is similar between laboratory strains and clinical isolates. It is intriguing that the mutants having Ser-84-to-Ala, Ser-85-to-Pro, and Glu-88-toLys mutations in GyrA had low-level resistance to sparfloxacin, while only the mutation of Ser-84 to Leu conferred high-level resistance to sparfloxacin. Sparfloxacin resistance is considered not to be affected largely by mutations other than Ser-84 to Leu. The bulkiness of the amino acid residue at this site appears to be important for resistance to sparfloxacin. Mutations in the gyrB gene were found for the first time. Considering that the levels of resistance to quinolones of the group 3 mutants (Asp-437 to Asn in GyrB) are lower than those ofgyrA mutants, gyrA mutants seem to have a selective advantage and gyrB mutants may not be observed as often in clinical isolates.
As a possible mechanism of action of quinolones, the quinolone pocket model has been proposed for E. coli, in which quinolones exert their action through their binding to a gyrase-DNA complex, and quinolone binding affinities for the complex are determined by both the GyrA and GyrB subunits in concert (42) . The existence of double mutations in the gyrA and gyrB genes may mean that the region around Ser-84 to Glu-88 in GyrA is in close proximity to Asp-437 and Arg-458 in GyrB. The quinolone resistance-determining regions of the gyrase subunits are presumed to constitute this putative quinolone pocket (39) . Mutations of these regions seem to prevent quinolones from approaching the pocket or from interacting with the DNA gyrase-DNA complex within the pocket to overcome the action of quinolones. In principle, the quinolone-gyrase interaction would be similar among bacterial organisms.
